All In Biotech

Drug Trial Radar · NCT01141439

Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management

A Retrospective Evaluation of the Effectiveness and Cost-effectiveness of HFA-BDP MDI (Qvar®) Compared With CFC-BDP MDI and FP MDI Used in the Management of Asthma in a Representative UK UK Primary Care Population

Last checked: Nov 19, 2026Latest source record: Mar 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

815,377

Actual

Start

Jan 2001

Primary completion

Jun 2007

Study completion Jul 2010

Sponsor

Lead sponsor
Research in Real-Life LtdResearch network
Sponsor type
Research network
Collaborators
Teva Branded Pharmaceutical Products R&D, Inc.
First posted
Jun 10, 2010

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 5 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study was to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing asthma in patients with evidence of persistent asthma, following the initiation and increased dose of inhaled corticosteroid (ICS) therapy using HFA-BDP (Qvar®) (either as initial therapy or as a step-up therapy) compared with the most commonly prescribed alternative ICS in the UK, CFC-beclometasone (BDP) and fluticasone (FP) as metered dose inhalers (MDIs). Qvar vs FP analyses were split between adults (12-60yrs) and paediatrics (5-11yrs).

Conditions

  • Asthma

Interventions

  • Extra-fine hydrofluoroalkane-beclomethasone dipropionateDrug

    Initiation of HFA-BDP (any dose) in steroid naive patients via MDI

  • Extra-fine hydrofluoroalkane-beclomethasone dipropionateDrug

    An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI

  • Fluticasone propionateDrug

    An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI

  • Beclomethasone dipropionateDrug

    An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI

  • fluticasone propionateDrug

    Initiation of FP (any dose) via MDI in steroid naive patient

  • Chlorofluorocarbon beclomethasone dipropionateDrug

    Initiation of CFC-BDP (any dose) via MDI in steroid naive patient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proxy asthma controlTime frame: One-year outcome period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General Practice Research Database

    London, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.